Prazosin

TEVA-PRAZOSIN (prazosin hydrochloride tablets) is indicated for: • the treatment of mild to moderate essential hypertension. It is employed in a general treatment program in association with a thiazide diuretic and/or other antihypertensive agents as needed for proper patient response.

TEVA-PRAZOSIN may be tried as a sole therapy in those patients in whom treatment with other agents caused adverse effects or is inappropriate. 1 Pediatrics Pediatrics ( 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of prazosin hydrochloride in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use.

2 Geriatrics Geriatrics (> 65 years of age): No data are available to Health Canada to establish differences in the safety and efficacy associated with the use of prazosin hydrochloride in geriatric patients.

INDICATIONS AND USAGE

Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.

Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Hypertension:

Hypovase is indicated in the treatment of all grades of essential (primary) hypertension and all grades of secondary hypertension of varied aetiology. It can be used as the initial and sole agent or it may be employed in a treatment regimen in conjunction with a diuretic and/or other antihypertensive drug as needed for proper patient response.

Congestive heart failure:

Hypovase may be used alone or added to the therapeutic regimen in those patients with congestive heart failure who are resistant or refractory to conventional therapy with diuretics and/or cardiac glycosides.

Raynaud’s phenomenon and Raynaud’s disease:

Hypovase is indicated for the symptomatic treatment of patients with Raynaud’s phenomenon and Raynaud’s disease.